Ernexa Therapeutics Inc. (ERNA) EPS (Basic) (2010 - 2026)
Ernexa Therapeutics' (ERNA) quarterly EPS (Basic) came in at -$6.95 in Q1 2026, up 87.94% YoY from -$3.7 in Q1 2025, and down 16.15% on a QoQ basis from -$5.99 in Q4 2025.
Ernexa Therapeutics Inc. (ERNA) EPS (Basic) (2010 - 2026) Analysis & Trends
Ernexa Therapeutics (ERNA) has 17 years of EPS (Basic) data on file, last reported at -$6.95 in Q1 2026.
- Quarterly EPS (Basic) rose 87.94% year-over-year to -$6.95 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.4 (up 95.56% YoY) and the FY2025 annual result came in at -$55.89, up 95.43% from the prior year.
- EPS (Basic) declined to -$6.95 in Q1 2026, from -$5.99 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$3.77 in Q3 2025 to a low of -$1.3 million in Q1 2022.
- A 5-year average of -$79157.6 and a median of -$387.54 in 2023 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2022 — EPS (Basic) sank 26704.51% — and 2023, when it jumped 99.97%.
- Tracing ERNA's EPS (Basic) over 5 years: stood at -$552.73 in 2022, then grew by 21.34% to -$434.76 in 2023, then soared by 63.55% to -$158.46 in 2024, then jumped by 96.22% to -$5.99 in 2025, then declined by 16.15% to -$6.95 in 2026.
- The last three EPS (Basic) figures came in at -$6.95 (Q1 2026), -$5.99 (Q4 2025), and -$3.77 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.40 |
| Mar 31, 2026 | -6.95 |
| Dec 31, 2025 | -5.99 |
| Sep 30, 2025 | -3.77 |
| Jun 30, 2025 | -15.19 |
| Mar 31, 2025 | -57.64 |
| Dec 31, 2024 | -158.46 |
| Sep 30, 2024 | -1,844.04 |
| Jun 30, 2024 | -383.79 |
| Mar 31, 2024 | -460.73 |
| Dec 31, 2023 | -434.76 |
| Sep 30, 2023 | -387.54 |
| Jun 30, 2023 | -319.33 |
| Mar 31, 2023 | -396.11 |
| Dec 31, 2022 | -552.73 |
| Sep 30, 2022 | -932.81 |
| Jun 30, 2022 | -434.38 |
| Mar 31, 2022 | -1.34 Mn |
| Dec 31, 2021 | -1,378.59 |
| Sep 30, 2021 | -12,757.57 |